NCT01972789 - Comparison of Treatment Regimens Using Ranibizumab: Intensive (Resolution of Intra- and Sub-retinal Fluid) vs Relaxed (Resolution of Intra-retinal Fluid and/or Sub-retinal Fluid >200µm at the Foveal Centre) | Biotech Hunter

Enrollment

349

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

February 28, 2017

Study Completion Date

February 28, 2017

Conditions

Subfoveal Choroidal Neovascularization CNV Secondary to Wet Age-related Macular Degeneration AMD

Interventions

DRUG

Ranibizumab

Ranibizumab solution for injection is commercially supplied in two presentations: as a pre-filled syringe (containing 1.65 mg of ranibizumab in 0.165 mL solution) and as a vial (containing 2.3 mg of ranibizumab in 0.23 mL solution) corresponding to a recommended dose of 0.5 mg (0.05 mL) given as a single intravitreal injection. It will be prescribed and administered by the investigator or designee

Trial Locations (16)

2000

Novartis Investigative Site, Sydney

2067

Novartis Investigative Site, Chatswood

2109

Novartis Investigative Site, North Ryde

2122

Novartis Investigative Site, Eastwood

2135

Novartis Investigative Site, Strathfield

2145

Novartis Investigative Site, Westmead

2150

Novartis Investigative Site, Parramatta

2170

Novartis Investigative Site, Liverpool

2220

Novartis Investigative Site, Hurtsville

2640

Novartis Investigative Site, Albury

3000

Novartis Investigative Site, Melbourne

3002

Novartis Investigative Site, Melbourne

5000

Novartis Investigative Site, Adelaide

6009

Novartis Investigative Site, Nedlands

7000

Novartis Investigative Site, Hobart

7249

Novartis Investigative Site, South Launceston